The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
Open accessAbstract
Summary: Background: The Crohn's Disease Activity Index (CDAI) is a measure of disease activity based on symptoms, signs and a laboratory test. The US Food and Drug Administration has indicated that patient reported outcomes (PRO s) should be the primary outcome in randomised controlled trials for Crohn's disease (CD). Aim: As no validated PRO exists for CD, to investigate whether CDAI diary card items could be modified for this purpose. Methods: Data from a trial of rifaximin‐extended intestinal release were used to identify cut‐points for stool frequency, pain and general well‐being using receiver operating characteristic curves with CDAI <150 as criterion. The operating properties of 2‐ and 3‐item PRO were evaluated using data from a trial of methotrexate in CD. Regression analysis determined PRO 2 and PRO 3 scores that correspond to CDAI‐defined thresholds of 150, 220 and 450 and changes of 50, 70 and 100 points. Results: Optimum cut‐points for CDAI remission were mean daily stool frequency ≤1.5, abdominal pain ≤1, and general well‐being score of ≤1 (areas under the ROC curve 0.79, 0.91 and 0.89, respectively). The effect estimates were similar using 2‐ and 3‐item PRO s or CDAI. PRO 2 and PRO 3 values corresponding to CDAI scores of 150, 220 and 450 points were 8, 14, 34 and 13, 22, 53. The corresponding values for CDAI changes of 50, 70 and 100, were 2, 5, 8 and 5, 9, 14. Responsiveness to change was similar for both PRO s. Conclusion: Patient reported outcomes derived from CDAI diary items may be appropriate for use in clinical trials for CD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.06.014 · Cited by 1,095
Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index
Thia, K., Faubion, W. A., Loftus, E. V., Persson, T., Persson, A., & Sandborn, W. J. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21400 · Cited by 134
Self-citation
Cited by
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Self-citationPeyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationDefining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
Peyrin-Biroulet, L., Panés, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., Colombel, J.-F., Hanauer, S. B., & Rycroft, B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.06.001 · Cited by 455
Self-citationVermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
D'Haens, G., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00467-6 · Cited by 433
Self-citationEfficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
“0, with neither worse than the baseline value) and endoscopic remission at week 12/16 (defined as SES-CD od 4 and a 2point reduction from baseline, with no subscore >1).(14) Key prespecified secondary endpoints assessed during the induction and maintenance periods at various timepoints included clinical remission 1.”
BackgroundMethodSelf-citationTargeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis
Pérez-Jeldres, T., Alvarez-Lobos, M., & Rivera-Nieves, J. (2021) · Drugs · doi:10.1007/s40265-021-01528-8 · Cited by 197
Gracie, D. J., Williams, C. J. M., Sood, R., Mumtaz, S., Bholah, H. M., Hamlin, J. P., & Ford, A. C. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.59 · Cited by 173
Romano, D., Chesterman, S., Fuller-Tyszkiewicz, M., Evans, S., Dober, M., Gearry, R., Gibson, P. R., Knowles, S., McCombie, A., O, E., et al. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad122 · Cited by 20
“The Patient-Reported Outcome–2 28 was adapted to measure the current activity of Crohn’s disease.”
MethodNaude, C., Skvarc, D., Maunick, B., Evans, S., Romano, D., Chesterman, S., Russell, L., Dober, M., Fuller-Tyszkiewicz, M., Gearry, R., et al. (2025) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003032 · Cited by 15
Evans, S., Olive, L., Dober, M., Knowles, S., Fuller-Tyszkiewicz, M., O, E., Gibson, P., Raven, L., Gearry, R., McCombie, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060272 · Cited by 15
Metadata
- Authors
- Khanna, R., Zou, G., D'Haens, G., Feagan, B. G., Sandborn, W. J., Vandervoort, M. K., Rolleri, R. L., Bortey, E., Paterson, C., Forbes, W. P., & Levesque, B. G.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-10-27
- Volume
- 41
- Issue
- 1
- Pages
- 77-86
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2161723853
- Cited by
- 242
- References
- 2
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.